SERA Profile
Sera Prognostics, Inc. is a leading women's health diagnostic company dedicated to advancing maternal and fetal health through innovative biomarker testing. The company specializes in the discovery, development, and commercialization of diagnostic tests designed to enhance pregnancy outcomes. One of its key offerings is the PreTRM test, a blood-based biomarker assay that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. This test aims to provide expectant mothers and healthcare providers with critical information to manage and mitigate risks associated with preterm birth.
In addition to its flagship PreTRM test, Sera Prognostics is expanding its product pipeline to address a range of pregnancy-related conditions. The company's research and development efforts are focused on developing diagnostic tests for preeclampsia, a serious pregnancy complication characterized by high blood pressure; molecular time-to-birth to better predict the timing of labor; gestational diabetes mellitus; fetal growth restriction; stillbirth; and postpartum depression. This comprehensive approach reflects Sera Prognostics’ commitment to addressing multiple facets of pregnancy-related health challenges.
Sera Prognostics was founded in 2008 and is headquartered in Salt Lake City, Utah. The company operates at the forefront of women's health diagnostics, leveraging cutting-edge biomarker research to deliver predictive and actionable insights. Its innovative testing solutions are designed to improve pregnancy management, reduce adverse outcomes, and support better health decisions for mothers and their babies.
With a focus on leveraging advanced technology and clinical research, Sera Prognostics continues to expand its impact in the field of maternal health. The company’s efforts to develop and commercialize its diagnostic tests are aimed at transforming pregnancy care and contributing to more informed and proactive management of pregnancy-related conditions.
|
